AgeX goes public on NYSE and share price immediately doubles. Congrats Aubrey de Grey, Michael West AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc, applying technology relating to cellular immortality and regenerative biology. “A growing sum of company and investment capital is making its way into the study of aging with the aim not only …
Category: Uncategorized
Word of Wisdom and Warning about CRISPR
A recent UK study has found CRISPR gene editing technique might cause more cell damage than originally thought. What? July 25th 2018. A The study, published in Nature Biotechnology, recommended specific testing for emerging and future CRISPR therapies, as resulting damage might not be detected with standard tests. Research author Professor Allan Bradley, from the Wellcome Sanger …